Explore Career Opportunities
We can’t wait to work with you!
focused on a new generation of adjuvanted subunit vaccines
Our Focus
We're dedicated to developing non-mRNA vaccines for unmet medical needs
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly and efficiently.
OUR PROGRAM: AMEZOSVATEIN
Shingles & Chickenpox
We are developing amezosvatein (CRV-101), a non-mRNA, adjuvanted subunit vaccine for shingles (herpes zoster) and chickenpox (varicella). We’ve enrolled over 800 participants in our extensive Phase 2 program comparing amezosvatein head-to-head versus Shingrix®, the most-used vaccine for prevention of shingles. Phase 2 data demonstrate the immune response to the highest dose of amezosvatein is non-inferior to Shingrix as measured by anti-gE antibody GMC measured at Day 84, or one month after the second vaccination. In a post hoc analysis, this non-inferiority was maintained out to Day 421, or one year after the second dose.
In a post-hoc analysis with nearly 19 months of follow-up, amezosvatein also provided protection from shingles cases comparable to Shingrix.
Alongside these data, amezosvatein demonstrated better tolerability when compared head-to-head with Shingrix in the Phase 2 trial. At the highest amezosvatein dose tested, the undesirable Grade 2 & 3 local and systemic reactogenicity events which interfere or prevent daily activities were 7.3% for amezosvatein versus 33.3% for Shingrix.
If these results are confirmed in Phase 3 trials, we hope amezosvatein will increase the number of people vaccinated for shingles by reducing vaccine hesitancy and second dose avoidance related to tolerability concerns. We also aim to address current accessibility issues given amezosvatein has been developed for easy scale-up at different production sites to meet global demand.
The current chickenpox vaccines are good examples of safe and effective vaccines making a big difference in reducing morbidity and mortality related to chickenpox. As live-attenuated virus (LAV) vaccines, however, they can be difficult to give to children and younger adults who have compromised immune systems. We are planning a Phase 1 trial of amezosvatein in immunocompromised children to address this unmet medical need.
__________________
Shingrix® is a registered trademark of GlaxoSmithKline, PLC.